Skip to Content
Merck
  • Which regimen is better for stem cell mobilization of lymphoma patients?

Which regimen is better for stem cell mobilization of lymphoma patients?

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis (2013-05-07)
Sinem Civriz Bozdağ, Emre Tekgündüz, Gamze Durgun, Abdurrahman Sarıca, Itır Şirinoğlu Demiriz, Serife Koçubaba, Fevzi Altuntaş
ABSTRACT

Although chemotherapy combined with G-CSF is an effective method for hematopoietic stem cell mobilization, standard chemotherapy protocol leading to best stem cell yield is not defined. In our study, we aimed to assess the impact of chemotherapy choice on mobilization outcome in lymphoma patients. Patients were mobilized with cyclophosphamide (n:15), ASHAP (n:11) or VGEPP (n:12) protocols. Groups were similar according to collected CD34+ cell count, total nucleated cell count and median apheresis days. Five out of fifteen (33%) patients could not be mobilized in Cy group but there was only one failed mobilization attempt in both salvage groups (9% with ASHAP vs 8% with VGEPP). In conclusion, we showed that VGEPP and ASHAP are safe protocols in terms of stem cell mobilization and have similar mobilization capacity as cyclophosphamide alone.

MATERIALS
Product Number
Brand
Product Description

Methylprednisolone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard
USP
Methylprednisolone hemisuccinate, United States Pharmacopeia (USP) Reference Standard
Methylprednisolone hydrogen succinate for performance test, European Pharmacopoeia (EP) Reference Standard